GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Current Ratio

ZEOX (Zeo ScientifiX) Current Ratio : 0.47 (As of Jul. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Zeo ScientifiX's current ratio for the quarter that ended in Jul. 2024 was 0.47.

Zeo ScientifiX has a current ratio of 0.47. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Zeo ScientifiX has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Zeo ScientifiX's Current Ratio or its related term are showing as below:

ZEOX' s Current Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.16   Max: 1.08
Current: 0.47

During the past 13 years, Zeo ScientifiX's highest Current Ratio was 1.08. The lowest was 0.02. And the median was 0.16.

ZEOX's Current Ratio is ranked worse than
89.55% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs ZEOX: 0.47

Zeo ScientifiX Current Ratio Historical Data

The historical data trend for Zeo ScientifiX's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Current Ratio Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.33 0.13 1.07 0.55

Zeo ScientifiX Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.55 0.48 0.39 0.47

Competitive Comparison of Zeo ScientifiX's Current Ratio

For the Biotechnology subindustry, Zeo ScientifiX's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Current Ratio distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Current Ratio falls into.



Zeo ScientifiX Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Zeo ScientifiX's Current Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Current Ratio (A: Oct. 2023 )=Total Current Assets (A: Oct. 2023 )/Total Current Liabilities (A: Oct. 2023 )
=2.202/4.01
=0.55

Zeo ScientifiX's Current Ratio for the quarter that ended in Jul. 2024 is calculated as

Current Ratio (Q: Jul. 2024 )=Total Current Assets (Q: Jul. 2024 )/Total Current Liabilities (Q: Jul. 2024 )
=1.725/3.634
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zeo ScientifiX  (OTCPK:ZEOX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Zeo ScientifiX Current Ratio Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. It is principally focusing on the development of innovative biological therapeutics for the treatment of chronic diseases and the provision of related services.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140